melanocortin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-18. Numbers and descriptions here follow the published literature rather than marketing material.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Dissolves readily in aqueous buffer |
| Typical storage temperature | -20 °C or below | Protect from light and moisture |
| Typical analytical method | Reversed-phase HPLC and LC-MS | Purity estimate plus mass confirmation |
| Unit of measure | Milligram per vial | Content varies by vendor |
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
== Characteristics == As a food ingredient, thaumatin is considered to be safe for consumption. In a chewing gum production plant, thaumatin has been identified as an allergen. Switching from using powdered thaumatin to liquid thaumatin reduced symptoms among affected workers. Additionally, eliminating contact with powdered gum arabic (a known allergen) resulted in the disappearance of symptoms in all affected workers. Thaumatin interacts with human TAS1R3 receptor to produce a sweet taste. The interacting residues are specific to old world monkeys and apes (including humans); only these animals can perceive it as sweet.
Protein folding is the physical process by which a protein, after synthesis by a ribosome as a linear chain of amino acids, changes from an unstable random coil into a more ordered three-dimensional structure. This structure permits the protein to become biologically functional or active. The folding of many proteins begins even during the translation of the polypeptide chain. The amino acids interact with each other to produce a well-defined three-dimensional structure, known as the protein's native state. This structure is determined by the amino-acid sequence or primary structure. The correct three-dimensional structure is essential to function, although some parts of functional proteins may remain unfolded, indicating that protein dynamics are important. Failure to fold into a native structure generally produces inactive proteins, but in some instances, misfolded proteins have a modified or toxic functionality. Several neurodegenerative and other diseases are believed to result from the accumulation of amyloid fibrils formed by misfolded proteins, the infectious varieties of which are known as prions. Many allergies are caused by the incorrect folding of some proteins because the immune system does not produce the antibodies for certain protein structures. Denaturation of proteins is a process of transition from a folded to an unfolded state. It happens in cooking, burns, proteinopathies, and other contexts. Residual structure present, if any, in the supposedly unfolded state may form a folding initiation site and guide the subsequent folding reactions.
3 spot in Entrepreneur magazine's 31st Annual Franchise 500, "the first and most comprehensive ranking in the world". This was the 17th year 7-Eleven was named in the top 10. In February 2010, 7-Eleven opened a concept store in DeLand, Florida, across from Stetson University, designed to meet LEED environmental standards. In 2017 they bought 1,110 C-Stores convenience stores from Sunoco in a deal valued at $3.3 billion and in 2024 acquired 204 Stripes convenience stores from Sunoco in a deal valued at $1 billion and finished integrating them in 2026. By 2015, 7-Eleven had over 55,000 stores across the world. In 2020, 7-Eleven announced it would purchase Speedway, 23,000 stores, for $21 billion. In 2021, 7-Eleven rolled out a $70 million ad campaign, their largest investment in advertising in years, doubling their market spending from the previous year. The commercials, directed by Harmony Korine, were to reflect the "evolution" of the chain's store format, drawing attention to, in part, the fact that "this isn't just gas station food, there's real restaurant quality food at 7-Eleven", according to CMO Marissa Jarrantt. On August 19, 2024, it was reported that Alimentation Couche-Tard—owner of competitor Circle K—had made a buyout offer for Seven & i Holdings. Later, on September 6, 2024, Seven & i Holdings rejected this offer as too low and rife with regulatory risk, although a "sweetened offer" might be considered. In October, a revised bid of $47 billion, 22% increase of the previous one, was presented.
Although statistics of the Soviet economy are notoriously unreliable and its economic growth difficult to estimate precisely, by most accounts, the economy continued to expand until the mid-1980s. During the 1950s and 1960s, it had comparatively high growth and was catching up to the West. However, after 1970, the growth, while still positive, steadily declined much more quickly and consistently than in other countries, despite a rapid increase in the capital stock (the rate of capital increase was only surpassed by Japan). Professor of Economic History Bob Allen contends that in the era in which the Soviet economy was publicly owned and planned (1928–1989), the Soviet Union's GDP per capita growth outpaced nearly all other world economies, trailing only Japan, South Korea, and Taiwan. Data shows that Soviet per capita growth expanded by a factor of 5.2, exceeding the growth rates of Western Europe at 4.0, and the US, Canada, Australia, and New Zealand at 3.3. Ultimately, the Soviet model of public ownership proved more effective at raising average incomes during this period than the world's primary industrialized capitalist systems. Scholar Christopher Davidson argued that, during the 1980s, the Reagan administration attempted to weaponize the global energy market against the USSR. At the request of CIA Director William J. Casey, Saudi Arabia flooded the market with oil, dropping the price from $28 to $10 per barrel, and draining Soviet foreign currency reserves. This was later described by a former CIA chief of staff as a "body blow to the Soviets.
Sources: en.wikipedia.org
Mumps vaccines are vaccines which prevent mumps. When given to a majority of the population they decrease complications at the population level. Effectiveness when 90% of a population is vaccinated is estimated at 85%. Two doses are required for long term prevention. The initial dose is recommended between 12 and 18 months of age. The second dose is then typically given between two years and six years of age. Usage after exposure in those not already immune may be useful. Side effects are usually mild. It may cause "slight soreness and swelling" at the site of injection, parotisis and mild fever. More significant side effects are rare. Evidence is insufficient to link the vaccine to complications such as neurological effects (beyond "occasional orchitis and sensorineural deafness"). The vaccine should not be given to people who are pregnant or have very poor immune system function. Poor outcomes among children of mothers who received the vaccine during pregnancy, however, have not been documented. Even though the vaccine is developed in chicken cells, it is generally safe to give to those with egg allergies. Most of the developed world and many countries in the developing world include it in their immunization programs often in combination with measles and rubella vaccine known as MMR. A formulation with the previous three and the varicella (chickenpox) vaccine known as MMRV is also available. As of 2005, 110 countries provided the vaccine as part of their immunization programs.
=== Legacy and claims of responsibility === Multiple claims of responsibility have continued to be put forward years after the recovery of the pumpkin. In 1999, editor-in-chief of the school paper Farhad Manjoo received an anonymous tip which potentially explained how the prank was carried out, involving a climb up the spire of the tower and the use of duct tape. The May 2000 Graduation issue of the Cornell Daily Sun stated that the prank was carried out by one Cornell student ringleader and two other Ithacan accomplices. In the Cornell Chimes Newsletter, it was stated that a student from the University of Montana, "Rob", confessed to former Head Chimesmaster Courtney Kimball that they had placed the pumpkin; Atlas Obscura deemed this inauthentic, though Cornell historian Ryan Earle stated that this was "the best source for how it happened." One rumor also claimed that the prankster's identity was passed down through each university archivist. In 2017, 20 years following the placement of the first pumpkin atop the tower, Manjoo, then reporter at The New York Times, called the event "the greatest prank in Cornell history" and that there was "no downside" in the pranksters coming forward as "all of that has passed now. Now they're just legends." Evan Fay Earle, the university archivist in 2017, stated that the pumpkin "continue[d] to generate interest at Cornell and [in] the community". The website about the pumpkin was partially brought back online for the anniversary.
=== Proton pumps === A proton pump is any process that creates a proton gradient across a membrane. Protons can be physically moved across a membrane, as seen in mitochondrial Complexes I and IV. The same effect can be produced by moving electrons in the opposite direction. The result is the disappearance of a proton from the cytoplasm and the appearance of a proton in the periplasm. Mitochondrial Complex III is this second type of proton pump, which is mediated by a quinone (the Q cycle). Some dehydrogenases are proton pumps, while others are not. Most oxidases and reductases are proton pumps, but some are not. Cytochrome bc1 is a proton pump found in many, but not all, bacteria (not in E. coli). As the name implies, bacterial bc1 is similar to mitochondrial bc1 (Complex III).
Sources: en.wikipedia.org
=== Isaac Kleiner === Dr. Isaac Kleiner (voiced by Harry S. Robins), a Black Mesa survivor, is one of the leading scientists in the human resistance to the Combine. His character design is based on the generic "nearly bald, glasses (Walter, as its model name suggests)" scientist model from the original Half-Life. Dr. Kleiner was one of Gordon Freeman's professors at MIT, recommending him for employment at Black Mesa to the Civilian Recruitment Division and working with him as part of the facility's Anomalous Materials team. He managed to survive the Resonance Cascade disaster of the first game with the aid of Eli Vance. In Half-Life 2, he operates an underground lab in an abandoned Northern Petrol building. A teleportation system, developed jointly by Kleiner and Eli Vance, connects to Vance's facility, several miles away. As a pet, Dr. Kleiner keeps a debeaked headcrab he calls 'Lamarr' (after the 1930s actress and inventor Hedy Lamarr). In Episode One, Kleiner appears on the video screens previously reserved for Dr. Breen's propaganda and instructs survivors to evacuate City 17, also encouraging them to procreate. He rallies people to prepare for the Combine's retaliation, stating that several new technologies developed during their occupation would be deployed as soon as possible to help fight the Combine. In Episode Two, Kleiner is working out of the White Forest Rocket Facility with Eli Vance and Arne Magnusson on a device intended to close the Combine Superportal created by the Citadel's destruction.
Two of the most significant differences between puberty in females and puberty in males are the age at which it begins, and the major sex steroids involved, the androgens and the estrogens. Although there is a wide range of normal ages, females typically begin the process of puberty around age 10½; males at ages 11½–12. Puberty generally ends between 15–17 for females and 16–17 for males. Females attain reproductive maturity about four years after the first physical changes of puberty appear. In contrast, males accelerate more slowly but continue to grow for about six years after the first visible pubertal changes. For males, the androgen testosterone is the principal sex hormone; while testosterone is produced, all males' changes are characterized as virilization. A substantial product of testosterone metabolism in males is the estrogen estradiol. The conversion of testosterone to estradiol depends on the amount of body fat and estradiol levels in males are typically much lower than in females. The male "growth spurt" also begins later, accelerates more slowly, and lasts longer before the epiphyses fuse. Although males are on average 2 centimetres (0.8 in) shorter than females before puberty begins, adult men are on average about 13 centimetres (5.1 in) taller than women. Most of this sex difference in adult heights is attributable to a later onset of the growth spurt and a slower progression to completion, a direct result of the later rise and lower adult male levels of estradiol. The hormonal maturation of females is considerably more complicated than in males.
=== Expansion and growth === When defined as "organizations with at least three state parties, a permanent headquarters or secretariat, as well as regular meetings and budgets", the number of IGOs in the world increased from about 60 in 1940 to about 350 in 1980, after which it has remained roughly constant.
Sources: en.wikipedia.org
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.
Reversed-phase liquid chromatography estimates purity, and mass spectrometry confirms molecular mass. Together they distinguish the intended peptide from truncated or modified forms. Sequence-level confirmation may use tandem mass spectrometry or amino acid analysis.
Because it is not made under pharmaceutical standards, purity and content can vary between vendors and batches. Independent testing has documented labeling discrepancies. A certificate of analysis from an accredited laboratory offers more assurance than a vendor's own claim.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.